Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
Globe Newswire•01/10/2026•07:30 ET
0
Key Highlights
- ➤AlloNK plus rituximab improved mean ClinESSDAI by 6.9 points at six months in 11 Sjögren disease patients.
- ➤Mean ESSPRI improved by 3.5 points at six months from an 8.0 baseline.
- ➤Mean stimulated salivary flow increased from 0.4 to 1.1 mL/min in eight patients.
- ➤73 Phase 2a patients had no CRS, ICANS, graft-versus-host disease or treatment discontinuations for adverse events.
- ➤Artiva (ARTV) is initiating a Phase 3 refractory rheumatoid arthritis trial during the second half of 2026.
Expert Statements
Fred Aslan, M.D., Chief executive officer of Artiva Biotherapeutics
“These updated Sjögren disease data build on the initial findings we presented at EULAR and show improvements across systemic disease activity, patient-reported symptoms and salivary function.”
Fred Aslan, M.D., Chief executive officer of Artiva Biotherapeutics
“We believe these results support continued evaluation of AlloNK plus rituximab as an outpatient-administered deep B-cell depleting regimen for patients with B-cell-driven autoimmune diseases.”
Fred Aslan, M.D., Chief executive officer of Artiva Biotherapeutics
“We look forward to following these patients to assess the durability of their responses.”
* Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren disease
* Mean stimulated salivary flow increased from 0.4 to 1.1 mL/min among eight patients with baseline hyposalivation and available six-month data
Get started
Create a free account to read the full story.